Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. [electronic resource]
Producer: 20070426Description: 164-75 p. digitalISSN:- 0301-0430
- Acute Disease
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Basiliximab
- Belgium -- epidemiology
- Biopsy
- Creatinine -- blood
- Cyclosporine -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Routes
- Drug Therapy, Combination
- Emulsions
- Enzyme Inhibitors -- administration & dosage
- Female
- Follow-Up Studies
- Germany -- epidemiology
- Graft Rejection -- blood
- Humans
- Immunosuppressive Agents -- administration & dosage
- Kidney Transplantation -- adverse effects
- Male
- Middle Aged
- Mycophenolic Acid -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Survival Rate
- Tablets, Enteric-Coated
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.